Get started
UroGen Pharma Ltd.UroGen Pharma Ltd.UroGen Pharma Ltd.

UroGen Pharma Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

URGN chart

Key stats

Market capitalization
‪495.79 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.72USD
Net income
‪−102.24 M‬USD
Revenue
‪82.71 M‬USD
Shares float
‪28.77 M‬
Beta (1Y)
1.88

About UroGen Pharma Ltd.

Sector
Health Technology
Industry
Biotechnology
CEO
Elizabeth Barrett
Website
urogen.com
Headquarters
Princeton
Employees (FY)
201
Founded
2004
ISIN
IL0011407140
FIGI
BBG00GFCC613
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of URGN is 14.53 USD — it has increased by 1.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange UroGen Pharma Ltd. stocks are traded under the ticker URGN.
UroGen Pharma Ltd. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
URGN stock is 5.24% volatile and has beta coefficient of 1.88. Check out the list of the most volatile stocks — is UroGen Pharma Ltd. there?
URGN earnings for the last quarter are −0.68 USD per share, whereas the estimation was −0.85 USD resulting in a 19.62% surprise. The estimated earnings for the next quarter are −0.68 USD per share. See more details about UroGen Pharma Ltd. earnings.
UroGen Pharma Ltd. revenue for the last quarter amounts to ‪20.85 M‬ USD despite the estimated figure of ‪20.03 M‬ USD. In the next quarter revenue is expected to reach ‪22.57 M‬ USD.
Yes, you can track UroGen Pharma Ltd. financials in yearly and quarterly reports right on TradingView.
URGN stock has fallen by 2.22% compared to the previous week, the month change is a 2.42% fall, over the last year UroGen Pharma Ltd. has showed a 46.92% increase.
URGN net income for the last quarter is ‪−26.02 M‬ USD, while the quarter before that showed ‪−21.88 M‬ USD of net income which accounts for −18.91% change. Track more UroGen Pharma Ltd. financial stats to get the full picture.
Today UroGen Pharma Ltd. has the market capitalization of ‪495.79 M‬, it has decreased by 0.83% over the last week.
No, URGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, URGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UroGen Pharma Ltd. stock right from TradingView charts — choose your broker and connect to your account.
URGN reached its all-time high on May 21, 2018 with the price of 69.57 USD, and its all-time low was 4.85 USD and was reached on May 25, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 24, 2024, the company has 201.00 employees. See our rating of the largest employees — is UroGen Pharma Ltd. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UroGen Pharma Ltd. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UroGen Pharma Ltd. stock shows the sell signal. See more of UroGen Pharma Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on UroGen Pharma Ltd. future price: according to them, URGN price has a max estimate of 54.00 USD and a min estimate of 18.00 USD. Read a more detailed UroGen Pharma Ltd. forecast: see what analysts think of UroGen Pharma Ltd. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UroGen Pharma Ltd. EBITDA is ‪−63.83 M‬ USD, and current EBITDA margin is −77.17%. See more stats in UroGen Pharma Ltd. financial statements.